0000000001075920
AUTHOR
M. Santoni
showing 2 related works from this author
RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC …
2012
ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…
The BaBar detector: Upgrades, operation and performance
2013
The BABAR detector operated successfully at the PEP-Il asymmetric e(+) e(-) collider at the SLAC National Accelerator Laboratory from 1999 to 2008. This report covers upgrades, operation, and performance of the collider and the detector systems, as well as the trigger, online and offline computing, and aspects of event reconstruction since the beginning of data taking.